Impact of Oral Therapies on High-Impact Sites in Psoriasis

Panelists discuss how scalp and other visible or sensitive areas can significantly affect quality of life, making effective oral options critical. Deucravacitinib demonstrates strong performance in scalp-specific trials with substantial improvements in itch and lesion clearance, while apremilast also shows notable but less robust outcomes.

Panelists discuss how choosing between therapies may depend on patient priorities, including symptom relief versus rapid aesthetic improvement. Deucravacitinib’s ability to achieve higher clearance rates supports its use in more stubborn or high-impact presentations, whereas apremilast remains valuable for milder, multifocal disease.

Panelists discuss how tailoring treatment by site involvement can optimize outcomes and patient satisfaction, reinforcing that oral agents offer important alternatives when topical or injectable therapies are impractical.